Next Article in Journal
Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences
Next Article in Special Issue
microRNA-34a as a Therapeutic Agent against Human Cancer
Previous Article in Journal
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
Previous Article in Special Issue
MicroRNA Library-Based Functional Screening Identified Androgen-Sensitive miR-216a as a Player in Bicalutamide Resistance in Prostate Cancer
Article Menu

Export Article

Correction published on 12 September 2016, see J. Clin. Med. 2016, 5(9), 81.

Open AccessReview
J. Clin. Med. 2015, 4(10), 1890-1907; doi:10.3390/jcm4101890

Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays

Department of Molecular Oncology, John Wayne Cancer Institute, Providence Saint John’s Health Center, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Takahiro Ochiya and Ryou-u Takahashi
Received: 7 July 2015 / Revised: 1 September 2015 / Accepted: 9 October 2015 / Published: 23 October 2015
(This article belongs to the Special Issue MicroRNAs: Novel Biomarkers and Therapeutic Targets for Human Cancers)
View Full-Text   |   Download PDF [288 KB, uploaded 12 September 2016]   |  

Abstract

An increasing number of studies have focused on circulating microRNAs (cmiRNA) in cancer patients’ blood for their potential as minimally-invasive biomarkers. Studies have reported the utility of assessing specific miRNAs in blood as diagnostic/prognostic biomarkers; however, the methodologies are not validated or standardized across laboratories. Unfortunately, there is often minimum limited overlap in techniques between results reported even in similar type studies on the same cancer. This hampers interpretation and reliability of cmiRNA as potential cancer biomarkers. Blood collection and processing, cmiRNA extractions, quality and quantity control of assays, defined patient population assessment, reproducibility, and reference standards all affect the cmiRNA assay results. To date, there is no reported definitive method to assess cmiRNAs. Therefore, appropriate and reliable methodologies are highly necessary in order for cmiRNAs to be used in regulated clinical diagnostic laboratories. In this review, we summarize the developments made over the past decade towards cmiRNA detection and discuss the pros and cons of the assays. View Full-Text
Keywords: circulating microRNA; blood; cancer patients; diagnosis; prognosis; circulating nucleic acids; next-generation sequencing circulating microRNA; blood; cancer patients; diagnosis; prognosis; circulating nucleic acids; next-generation sequencing
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S.B. Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J. Clin. Med. 2015, 4, 1890-1907.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top